Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
TriVascular raises $60 million: European launch of the firm's Ovation abdominal aortic aneurysm stent graft later this year will be aided by $60 million in new funding led by Pinnacle Ventures, including a "Series C" equity financing and growth capital venture debt, the firm announced July 12. The low-profile stent system is designed to expand the patient population suitable for endovascular aortic repair by addressing a wider range of diseased anatomy, the company explains. European study implants began last March to support a CE mark application, and the firm commenced its U.S. pivotal study in May. A 2008 spinout from Boston Scientific headquartered in Santa Rosa, Calif., TriVascular notes that it also is developing a version of Ovation for thoracic aortic aneurysms (1"The Gray Sheet" April 7, 2008)
You may also be interested in...
Waiting For Exhale: Emphysema Researchers Call For New Stent Designs, More Analysis
New stent designs and placement techniques are needed to develop an interventional device that successfully treats severe emphysema, researchers said following publication of disappointing study results for a drug-eluting stent system intended to create airway passages in the lung.
Waiting For Exhale: Emphysema Researchers Call For New Stent Designs, More Analysis
New stent designs and placement techniques are needed to develop an interventional device that successfully treats severe emphysema, researchers said following publication of disappointing study results for a drug-eluting stent system intended to create airway passages in the lung.
BioMimetic Therapeutics' Augment
Synthetic bone graft PMA is on track for review by FDA's Orthopedic and Rehabilitation Devices Panel by early 2011, and approval in mid-2011, according to the company. BioMimetic announced Sept. 8 that a recent meeting with FDA on its PMA, which was filed by the agency in May, raised no "unexpected issues that would impact the timing" for the panel review (1"The Gray Sheet" July 19, 2010). The firm simultaneously announced that its Augment Injectable Bone Graft will also be regulated as a device following a recent Request for Designation submission. BioMimetic says it aims to start a U.S. trial for the injectable formulation of Augment in the fourth quarter, pending investigational device exemption clearance